A small diameter bioactive prosthetic vascular graft with activated protein C (546.9)

To date, there are no small (less than 5 mm) internal diameter vascular grafts that are FDA approved for clinical use due to high failure rates from thrombosis and increased cell proliferation, conditions that may be improved with use of enhanced bioengineered graft materials. Here we show that long term graft viability and patency can be improved by covalently binding activated protein C (APC) to prosthetic vascular graft surfaces due to APC’s...